Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | ASTRAZEN AstraZeneca Pharma India Limited Pharma · Small | AJANTPHARM Ajanta Pharma Limited Pharma · Large | GLAXO GlaxoSmithKline Pharmaceuticals Limited Pharma · Large | EMCURE Emcure Pharmaceuticals Limited Pharma · Large |
|---|---|---|---|---|
| Final Score | 42 | 54 | 60 | 55 |
| Verdict | WATCHLIST | FAIR VALUE | UNDERVALUED | FAIR VALUE |
| Style | WATCHLIST | Premium Compounder | Premium Compounder | Premium Compounder |
| Piotroski | 6/9 | 8/9 | 8/9 | 8/9 |
| Valuation | 0/30 | 4/30 | 4/30 | 5/30 |
| Growth | 12/25 | 13/25 | 11/25 | 16/25 |
| Quality | 14/20 | 17/20 | 20/20 | 15/20 |
| Balance Sheet | 10/15 | 11/15 | 12/15 | 10/15 |
| Cash Flow | 3/10 | 4/10 | 7/10 | 4/10 |
| Price | ₹8,453 | ₹3,017.2 | ₹2,194.7 | ₹1,743 |
| P/E | 112.00 | 35.10 | 36.20 | 34.40 |
| P/B | 24.64 | 8.20 | 16.30 | 6.59 |
| ROE | 23.30% | 25.40% | 48.40% | 20.10% |
| ROCE | 29.30% | 32.30% | 65.10% | 24.00% |
| Debt / Equity | 0.13 | 0.06 | 0.02 | 0.31 |
| FCF Yield | 0.02% | 0.27% | 3.51% | — |
| Dividend Y | 0.37% | 0.94% | 2.61% | 0.17% |
| Altman Z | 9.08 | 8.92 | 8.62 | 6.66 |
| Promoter % | 75.00% | 66.25% | 75.00% | 77.87% |
| Mkt Cap (₹Cr) | 21500.00 | 37091.00 | 36995.00 | 32533.00 |
| Graham # | ₹767.47 | ₹829.71 | ₹429.38 | ₹535.11 |
| Fair PE | 42.0 | 42.3 | 42.0 | 42.0 |
| MoS % | -168.3% | +15.6% | +14.6% | +14.9% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startASTRAZEN116
AJANTPHARM105
GLAXO86
EMCURE125